• Molecular NameTinidazole
  • Synonymtinidazole
  • Weight247.275
  • Drugbank_IDDB00911
  • ACS_NO19387-91-8
  • Show 3D model
  • LogP (experiment)-0.35
  • LogP (predicted, AB/LogP v2.0)-0.44
  • pkaN/A
  • LogD (pH=7, predicted)-0.44
  • Solubility (experiment)19.9 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-1.83
  • LogSw (predicted, AB/LogsW2.0)8.42
  • Sw (mg/ml) (predicted, ACD/Labs)3.66
  • No.of HBond Donors0
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds5
  • TPSA109.17
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn anti-parasitic drug used against protozoan infections.
  • Absorption_value100.0
  • Absorption (description)Rapidly and completely absorbed under fasting conditions. Administration with food results in a delay in Tmax of approximately 2 hours and a decline in Cmax of approximately 10% and an AUC of 901.6 ± 126.5 mcg hr/mL.
  • Caco_2N/A
  • Bioavailability98.0
  • Protein binding12.0
  • Volume of distribution (VD)0.7 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic, mainly via CYP3A4. Tinidazole, like metronidazole, is significantly metabolized in humans prior to excretion. Tinidazole is partly metabolized by oxidation, hydroxylation and conjugation. Tinidazole is the major drug-related constituent in plasma after human treatment, along with a small amount of the 2-hydroxymethyl metabolite.
  • Half life12~17 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)LD50> 2,000 mg/kg
  • LD50 (mouse)LD50>3,600 mg/kg